Safety and efficacy of combination immunotherapy with interferon Alfa-2b and tremelimumab in patients with stage IV melanoma

Journal of Clinical Oncology

Volumn 30, Issue 3, 2012, Pages 322-328

  Tarhini, Ahmad A ^a   Cherian, John ^a   Moschos, Stergios J ^a   Tawbi, Hussein A ^a   Shuai, Yongli ^a   Gooding, William E ^a   Sander, Cindy ^a   Kirkwood, John M ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA INTERFERON; ALPHA2B INTERFERON; ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; CREATINE KINASE; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; TEMOZOLOMIDE; TICILIMUMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANXIETY; ARTICLE; AUTOIMMUNE DISEASE; BRAIN METASTASIS; BRONCHOSPASM; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COLITIS; DEHYDRATION; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; EYE CANCER; FATIGUE; FEMALE; HEART ATRIUM FIBRILLATION; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPOGONADISM; HYPOTHYROIDISM; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SKIN CANCER; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; RECOMBINANT PROTEINS; SKIN NEOPLASMS;

EID: 84856069688     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.5394     Document Type: Article

References (60)

1. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011
2. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526, 2011
3. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
4. Tatsumi T, Kierstead LS, Ranieri E, et al: Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 196:619-628, 2002 (Pubitemid 35024440)
5. Nishimura T, Nakui M, Sato M, et al: The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol 46:S52-S61, 2000 (suppl)
6. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17, 1996 (Pubitemid 26019991)
7. Kirkwood JM, Richards T, Zarour HM, et al: Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: The E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer 95:1101-1112, 2002 (Pubitemid 34925363)
8. Wang W, Edington HD, Rao UN, et al: Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res 13:1523-1531, 2007 (Pubitemid 46450444)
9. Paquette RL, Hsu NC, Kiertscher SM, et al: Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol 64:358-367, 1998 (Pubitemid 28409243)
10. Parlato S, Santini SM, Lapenta C, et al: Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: Importance for the rapid acquisition of potent migratory and functional activities Blood 98:3022-3029, 2001
11. Brinkmann V, Geiger T, Alkan S, et al: Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J Exp Med 178:1655-1663, 1993 (Pubitemid 23318444)
12. Wenner CA, Güler ML, Macatonia SE, et al: Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development. J Immunol 156:1442-1447, 1996
13. Rogge L, Barberis-Maino L, Biffi M, et al: Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med 185:825-831, 1997 (Pubitemid 27119866)
14. Palmer KJ, Harries M, Gore ME, et al: Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC). Clin Exp Immunol 119:412-418, 2000 (Pubitemid 30146335)
15. Carballido JA, Moltó LM, Manzano L, et al: Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder. Cancer 72:1743-1748, 1993 (Pubitemid 23249305)
16. Yurkovetsky ZR, Kirkwood JM, Edington HD, et al: Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 13:2422-2428, 2007 (Pubitemid 46698593)
17. Tough DF: Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation. Leuk Lymphoma 45:257-264, 2004
18. Moschos SJ, Edington HD, Land SR, et al: Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 24:3164-3171, 2006 (Pubitemid 46638955)
19. Brunet JF, Denizot F, Luciani MF, et al: A new member of the immunoglobulin superfamily-CTLA-4. Nature 328:267-270, 1987
20. Khattri R, Auger JA, Griffin MD, et al: Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses. J Immunol 162:5784-5791, 1999 (Pubitemid 29314929)
21. Tivol EA, Borriello F, Schweitzer AN, et al: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541-547, 1995
22. Waterhouse P, Penninger JM, Timms E, et al: Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985-988, 1995
23. Lin H, Rathmell JC, Gray GS, et al: Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. J Exp Med 188:199-204, 1998 (Pubitemid 28328618)
24. Krummel MF, Allison JP: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182:459-465, 1995
25. Hurwitz AA, Foster BA,**Kwon ED, et al: Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60(9):2444-2448, 2000 (Pubitemid 30262435)
26. Kwon ED, Foster BA, Hurwitz AA, et al: Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A 96:15074-15079, 1999 (Pubitemid 30019767)
27. van Elsas A, Hurwitz AA, Allison JP: Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190:355-366, 1999 (Pubitemid 29374833)
28. Hanson DC, Canniff PC, Primiano MJ, et al: Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206. Proc Am Assoc Cancer Res 45, 2004 (abstr 3802)
29. Ribas A, DT, Comin-Anduix B, de la Rocha P, et al: Changes in intratumoral immune cell infiltrates, Foxp3 and indoleamine 2, 3-dioxygenase (IDO) expression with the CTLA4 blocking MAB CP-675,206. J Immunother 29:636, 2006
30. Kirkwood JM, Bender C, Agarwala S, et al: Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 20:3703-3718, 2002 (Pubitemid 34983231)
31. Hauschild A, Gogas H, Tarhini A, et al: Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: Expert opinion. Cancer 112:982-994, 2008 (Pubitemid 351304581)
32. Korn EL, Liu PY, Lee SJ, et al: Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26:527-534, 2008 (Pubitemid 351264344)
33. Tarhini AA, Kirkwood JM: Tremelimumab (CP-675,206): A fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers. Expert Opin Biol Ther 8:1583-1593, 2008
34. Marshall M, Ribas A, Huang B: Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanoma. J Clin Oncol 28:231s, 2010 (abstr 2609)
35. Wolchok JD, Ibrahim R, DePril V, et al: Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment. J Clin Oncol 26:137s, 2008 (suppl; abstr 3020)
36. Kirkwood JM, Lorigan P, Hersey P, et al: A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. J Clin Oncol 26:488s, 2008 (suppl; abstr 9023)
37. Ribas A, Hauschild A, Kefford R, et al: Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol 26:485s, 2008 (suppl; abstr LBA9011)
38. Gogas H, Ioannovich J, Dafni U, et al: Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:709-718, 2006 (Pubitemid 43247141)
39. Krauze MT, Tarhini A, Gogas H, et al: Prognostic significance of autoimmunity during treatment of melanoma with interferon. Semin Immunopathol 33:385-391, 2011
40. Atkins MB, Mier JW, Parkinson DR, et al: Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 318:1557-1563, 1988
41. Weijl NI, van der Harst D, Brand A, et al: Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol 11:1376-1383, 1993 (Pubitemid 23199144)
42. Scalzo S, Gengaro A, Boccoli G, et al: Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma. Eur J Cancer 26:1152-1156, 1990
43. Krouse RS, Royal RE, Heywood G, et al: Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J Immunother Emphasis Tumor Immunol 18:272-278, 1995 (Pubitemid 26089626)
44. Phan GQ, Attia P, Steinberg SM, et al: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19:3477-3482, 2001 (Pubitemid 32730084)
45. Becker JC, Winkler B, Klingert S, et al: Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer 73(6):1621-1624, 1994 (Pubitemid 24085261)
46. Rosenberg SA, White DE: Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 19:81-84, 1996 (Pubitemid 26127369)
47. Franzke A, Peest D, Probst-Kepper M, et al: Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol 17:529-533, 1999 (Pubitemid 29075239)
48. Phan GQ, Yang JC, Sherry RM, Hwu P, et al: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100:8372-8377, 2003 (Pubitemid 36842552)
49. Sanderson K, Scotland R, Lee P, et al: Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 23:741-750, 2005 (Pubitemid 46224173)
50. Dranoff G, Jaffee E, Lazenby A, et al: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A, 90:3539-3543, 1993 (Pubitemid 23111402)
51. Ribas A, Camacho LH, Lopez-Berestein, et al: Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol, 23:8968-8977, 2005 (Pubitemid 46217464)
52. Stuckert JJ, Tarhini AA, Lee S, et al: Interferon alfa-induced autoimmunity and serum S100 levels as predictive and prognostic biomarkers in high-risk melanoma in the ECOG-intergroup phase II trial E2696. J Clin Oncol 25:473s, 2007 (suppl; abstr 8506)
53. Deichmann M, Kahle B, Moser K, et al: Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer 91:699-702, 2004 (Pubitemid 39141627)
54. Marnell L, Mold C, Du Clos TW: C-reactive protein: Ligands, receptors and role in inflammation. Clin Immunol 117:104-111, 2005 (Pubitemid 41407719)
55. Enocsson H, Sjöwall C, Skogh T, et al: Interferon-alpha mediates suppression of C-reactive protein: Explanation for muted C-reactive protein response in lupus flares? Arthritis Rheum 60:3755-3760, 2009
56. Hamid O, Chasalow SD, Tsuchihashi Z, et al: Association of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab. J Clin Oncol 27:463s, 2009 (suppl; abstr 9008)
57. Hamid O: Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study. J Clin Oncol 26:489s, 2008 (suppl; abstr 9025)
58. Wolchok JD, Neyns B, Linette G, et al: Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11:155-164, 2010
59. Gabrilovich DI, Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162-174, 2009
60. Strauss L, Bergmann C, Szczepanski M, et al: A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13:4345-4354, 2007 (Pubitemid 47219698)